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a  b  s  t  r  a  c  t
Leishmaniasis  is a major  health  problem  and  it is  estimated  that  12 million  people  are  currently  infected.  A
vaccine which  could  cross-protect  people  against  different  Leishmania  spp.  would  facilitate  control  of  this
disease  as more  than  one  species  of  Leishmania  may  be  present.  In this  study  the ability  of a  DNA  vaccine,
using  the  full  gene  sequence  for  L. donovani  gamma  glutamyl  cysteine  synthetase  (GCS)  incorporated  in
the pVAX  vector  (pVAXGCS),  and  a protein  vaccine,  using  the  corresponding  recombinant  L.  donovani
GCS  protein  (LdGCS),  to protect  against  L. major  or L.  mexicana  infection  was  evaluated.  DNA  vaccinationeywords:
amma  glutamyl cysteine synthetase
eishmania
accine
gave transient  protection  against  L.  major  and  no  protection  against  L.  mexicana  despite  signiﬁcantly
enhancing  speciﬁc  antibody  titres  in  vaccinated  infected  mice  compared  to infected  controls.  Vaccination
with  the  LdGCS  protected  against  both  species  but only  if the  protein  was  incorporated  into  non-ionic
surfactant  vesicles  for L.  mexicana.  The  results  of  this  study  indicate  that  a L. donovani  GCS  vaccine  could
be used  to vaccinate  against  more  than one  Leishmania  species  but  only  if the  recombinant  protein  is
used.
. Introduction
Leishmaniasis is a disease caused by infection with vector
orne protozoan parasite Leishmania.  The outcome of infection
epends on a number of different factors, which include, the
nfecting species, the immune response, the genetics of the host,
nd the presence of other infections, e.g. human immunodeﬁ-
iency virus (reviewed by [1]). The incidence of leishmaniasis is
ikely to be underestimated because it is not a reportable dis-
ase in many countries but ﬁgures published by the World Health
rganisation indicate that 12 million people are currently infected
ith leishmaniasis, and that the cutaneous form is responsi-
le for the majority of cases (http://www.who.int/leishmaniasis/
urden/magnitude/burden magnitude/en/index.html). There are a
imited number of drugs available for the treatment of leishmania-
is and the emergence of drug resistance, which is prevalent in some
reas for antimonial drugs and likely to emerge for miltefosine,
ill limit the options even further [2,3]. Control of leishmaniasis is
ikely to involve a concerted effort involving treatment of existing
∗ Corresponding author. Tel.: +44 141 5483823.
E-mail address: k.carter@strath.ac.uk (K.C. Carter).
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cases, control of the vector and prevention of infection using an
effective vaccine but at present there is no vaccine clinically avail-
able to treat the disease. A variety of different vaccines, based on
killed promastigote parasites, recombinant proteins or using cod-
ing gene sequences for Leishmania proteins, have been tested in
animal models. A limited number of these potential vaccines have
been used in canine studies, since canine leishmaniasis is a veteri-
nary disease and the dog can act as an animal reservoir, and even
fewer have been used in clinical trials (reviewed by [4]). For exam-
ple, Leish-111f, a recombinant polypeptide protein vaccine that
consists of thiol-speciﬁc antioxidant (TSA), Leishmania major stress-
inducible protein 1 (LmSTI1), and Leishmania elongation initiation
factor (LeIF), has been used in laboratory animals, dogs and Phase
I and II human clinical trials. It is formulated with the adjuvant
monophosphoryl lipid A as a stable emulsion (MPL-SE). In murine
studies this vaccine protected against both visceral and cutaneous
leishmaniasis but had variable results in subsequent canine stud-
ies. This vaccine failed to give any protection against L. infantum in
one study [5] but did induce some protection in another, which was
enhanced by co-treatment with Glucantime® [6].  In a more recent
study, using a different vaccination protocol, dogs given adjuvant
alone were as protected against natural L. infantum infection as dogs
immunised with Leish-111f MPL-SE [7]. The authors did however
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eport that in human studies the vaccine was more effective than
he adjuvant alone against cutaneous leishmaniasis. It is likely that
ny effective vaccine would require the presence of more than one
arasite antigen and therefore studies to identify potential vaccine
andidates which could be used in a multi-component vaccine are
seful. Ideally a vaccine that protects against all type of leishma-
iasis is required as this would be more cost effective to produce
nd would be effective in areas where different species occur. We
ave shown in previous studies that vaccination with either a plas-
id  containing the gene sequence of L. donovani gamma  glutamyl
ysteine synthetase (pVAXGCS [8]) or recombinant L. donovani
amma  glutamyl cysteine synthetase protein (LdGCS [9]) pro-
ected mice against infection with L. donovani. In this study the
bility of both vaccines to protect against cutaneous leishmania-
is caused by L. major or L. mexicana was assessed to determine
hether either vaccine was a candidate for a generic antileishma-
ial vaccine.
. Materials and methods
.1. Reagents
Pharmingen capture and detection antibodies and standards for
FN- and IL-4 and alkaline phosphatase conjugate were obtained
rom Insight Biotechnology (Wembley, UK). All other reagents were
f analytical grade.
.2. Animals and parasites
Age matched BALB/c male or female mice (20–25 g) in-house
red at University of Strathclyde were used in this study. Leish-
ania major (strain MRHO/IR/75/ER) and L. mexicana (strain
NYC/BZ/62/M379) were used in experiments and maintained
y serial passage through BALB/c mice. Animals were infected
ith amastigotes, obtained from the lesion of an infected mouse,
r promastigotes, obtained by culturing part of a lesion from an
nfected animal in RPMI-1640 medium containing 10% (v/v) heat-
nactivated foetal calf serum (Gibco, UK). Studies were carried out in
ccordance with local ethical approval and under United Kingdom
ome Ofﬁce regulations.
.3. LdGCS recombinant protein and DNA vaccines
His-tagged recombinant L. donovani GCS protein (LdGCS),
rocessed to remove endotoxin, was produced as described by Hen-
iquez et al. [8] and endotoxin free plasmid as either empty vector or
ontaining the full gene sequence for L. donovani GCS (pVAXGCS)
as produced as described by Carter et al. [9].  Aliquots of LdGCS,
VAXGCS or plasmid alone (pVAX) were stored at −20 ◦C until
equired.
.4. Production of NIV
One hundred and ﬁfty micromolar vesicle constituents, consist-
ng of 3:3:1 molar ratio of mono-n-hexadecyl ether tetraethylene
lycol, cholesterol, and dicetyl phosphate was melted by heating
t 130 ◦C for 5 min. The molten mixture was cooled to 70 ◦C, and
ydrated with 5 ml  of preheated (70 ◦C) water to form ‘empty’
on-ionic surfactant vesicles (NIV). Vesicular formulations were
omogenized at 8000 ± 100 rpm for 15 min  at 70 ◦C, using a Sil-
erson mixer, ﬁtted with a 5/8 in. tubular work head. One or 2 ml
liquots of the NIV were stored at −70 ◦C before freeze-drying and
hen storing at −20 ◦C until required. NIV were rehydrated with
dGCS solution (0.5 mg/ml, PBS pH 7.4, LdGCS-NIV) just prior to
se. 30 (2012) 1357– 1363
2.5. Immunisation studies
The day of infection was  day 0 so that vaccination occurred pre-
infection on days −28 and −14. In studies using LdGCS mice (n = 4
or 5/treatment) were immunised by subcutaneous injection with
50 g LdGCS solution (0.5 mg/ml  PBS pH 7.4) or 50 g LdGCS-
NIV (0.5 mg/ml  PBS pH 7.4) In studies using the DNA vaccine mice
were immunised by intramuscular injection into each thigh mus-
cle with 25 g pVAXGCS (1 mg/ml, PBS pH 7.4) or 25 g plasmid
alone (pVAX, 1 mg/ml  PBS pH 7.4). On day 0 immunised mice and
an age and sex-matched control group were infected by subcuta-
neous injection into the shaven rump with 1 × 107 promastigotes or
2 × 106 amastigotes parasites. Amastigotes are more infective than
promastigotes and this difference in inoculum results in similar rate
of parasite growth in animals. Parasite growth was determined by
measuring lesion size (mm) over the course of infection and experi-
ments were terminated when the lesion size of any of the mice was
greater than 12 mm.  All studies were carried out in accordance with
UK. Home Ofﬁce regulations and repeated a minimum of twice so
that results were conﬁrmed.
2.6. Assessment of immunological responses
End point titres of parasite speciﬁc IgG1 and IgG2a present in
the serum against the LdGCS protein was  determined by ELISA
assays [9].  At early time points the lowest serum dilution tested was
1:100, while at later time points, when high antibody titres were
obtained, the lowest dilution tested was 1:1000. Single cell suspen-
sions, prepared from the spleens of mice, were used in in vitro assays
where cells were incubated with medium alone (unstimulated
controls), Concanavalin A (ConA, 5 g/ml, stimulated controls) or
LdGCS protein (25 g/ml) to stimulate the production of cytokines
or nitrite. Cell supernatants were stored at −20 ◦C until nitrite or
cytokine were determined as previously described [9].
2.7. Phylogenetic studies
Protein sequences for GCS for L. donovani (AAQ73826.2) and L.
major (XP 001682576.1) were obtained from NCBI and were used
to search the L. mexicana database on GeneDB.org. GeneDB is part
of the Sanger Institute Pathogen Genomics activities. The sequence
LmxM18 1660.pep corresponds to the L. mexicana GCS sequence.
Protein sequences from all three species were aligned using the
ClustalW2 Multiple sequence alignment tool at EMBL EBI [10] using
the default web based parameters.
2.8. Statistical analysis of data
Lesion size data, cytokine, antibody and nitrite data were ana-
lysed using a non-parametric tests using the Statview® version
5.0.1 software package. Data was analysed using a Mann Whit-
ney U test if two  treatments were analysed a Kruskal Wallis test
followed by Dunns ad hoc test was used to determine signiﬁcant dif-
ferences for three treatments. Results were considered signiﬁcantly
different if a P value of <0.05 was obtained.
3. Results
3.1. Comparison of L. donovani, L. major and L. mexicana GCS
gene sequence
The alignment for the gene sequence for GCS for the three
Leishmania species is shown in Fig. 1. There is considerable homol-
ogy (87.6%) in the sequence of the protein for all three species.
There was 95% identity and 97% similarity between L. donovani and
L. major, 91% identity and 95% similarity between L. donovani and
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tig. 1. Alignment for GCS gene sequence from L. donovani, L. major and L. mexica
.  mexicana (GeneDB LmxM18 1660.pep) were aligned using the ClustalW2 Multipl
arked  (*) are conserved across all three species. Residues marked (:) are conserve
paces  designate a lack of conservation.
. mexicana and 89% identity and 94% similarity between L. major
nd L. mexicana.
.2. Immunisation with pVAXGCS induced transient protection
gainst L. major but no protection against L. mexicana
Immunisation with pVAXGCS signiﬁcantly delayed lesion
rowth in mice infected with L. major (P < 0.05) at one time point
ost-infection but failed to inﬂuence lesion development in L. mex-
cana infected mice (Fig. 2). Speciﬁc antibody levels and cytokine
roduction by splenocytes stimulated in vitro with speciﬁc antigen
ere determined at the end of the experiment to determine the
ype of immune response present in infected mice. Immunisationquences for GCS from L. donovani (AQQ73826.2), L. major (XP 001682576.1), and
uence Alignment Tool and show 87.6% homology across all three species. Residues
no acid substitutions and those marked (.) are semi-conserved substitutions. Blank
with pVAXGCS signiﬁcantly enhanced speciﬁc IgG1 (P < 0.01) but
not IgG2a titres in L. major infected mice and enhanced both IgG1
(P < 0.01) and IgG2a (P < 0.05) levels in L. mexicana infected mice
compared to control values (Fig. 3). Similar amounts of IFN-, IL-4
and nitrite were produced by antigen stimulated and unstimulated
control splenocytes from vaccinated or control mice infected with
L. major or L. mexicana (Tables 1 and 2). ConA stimulation of cells
from all three groups of mice given L. major or L. mexicana produced
similar enhanced levels of IFN- and nitrite compared to corre-
sponding unstimulated controls (P < 0.05, Tables 1 and 2). IL-4 levels
in cell supernatants were also signiﬁcantly higher than unstimu-
lated controls in mice given L. major (P < 0.05, Table 1) whereas IL-4
production by ConA stimulated cells from all three groups of mice
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Fig. 2. The effect of vaccination with different vaccines on the progression of L. major and L. mexicana infection. Mice were vaccinated intramuscularly on days −28 and
−14  with 50 g pVAX (plasmid alone, pVAX), 50 g pVAXGCS (pVAXgGCS), 50 g LdGCS protein (gGCS) or LdGCS protein incorporated into NIV (gGCS-NIV). On  day 0
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taccinated or uninfected control mice were infected by subcutaneous injection in 
tudies) or L. mexicana (data for mice were infected with 1 × 107 promastigotes sho
accine). Parasite growth was  monitored over the course of infection by measuring
as similar to corresponding unstimulated control values in mice
nfected with L. mexicana (Table 2).
.3. Immunisation with LdGCS-NIV induced protection against
oth L. major and L. mexicana whereas LdGCS alone only
rotected against L. majorIt was possible that vaccination with the whole gene sequence
f L. donovani GCS did not induce any protection against L. mex-
cana and limited protection against L. major infection because L.
onovani GCS protein translated from the plasmid vector had low
ig. 3. The effect of vaccination with different vaccines on the antibody responses of L. m
he  experiments for mice from Fig. 2. **P < 0.01, *P < 0.05 compared to relevant infected coaven rump with L. major (1 × 107 promastigotes in both protein and DNA vaccine
r DNA vaccine; data for mice infected with 2 × 106 amastigotes shown for protein
 diameter. *P < 0.05 compared to relevant infected control value.
similarity to the native GCS produced by the other Leishmania
spp. Therefore the ability of LdGCS alone or LdGCS formu-
lated into non-ionic surfactant vesicles (LdGCS-NIV) to confer
cross-protection against L. major and L. mexicana infection was
determined. Both formulation of LdGCS gave a similar delay in
lesion growth in L. major infected mice with the mean lesion size in
vaccinated mice being lower at all time points compared to control
values. However lesion size in vaccinated mice was  only signiﬁ-
cantly lower than control values at day 33 post-infection (Fig. 2).
Only vaccination with LdGCS-NIV signiﬁcantly enhanced speciﬁc
antibody titres against the recombinant antigen in L. major infected
ajor and L. mexicana infected mice. Speciﬁc IgG1 and IgG2a titres at termination of
ntrol value.
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Table 1
The effect of vaccination with different vaccines on the immune responses of L. major infected mice. Mice were vaccinated intramuscularly on days −28 and −14 with 50 g
pVAX  (plasmid alone), 50 g pVAXGCS, 50 g LdGCS protein or 50 g LdGCS protein incorporated into NIV (LdGCS-NIV) and infected on day 0, along with infection
controls, with 1 × 107 L. major promastigotes. Splenocytes isolated from infected animals at the end of the experiment were incubated with medium alone (unstimulated),
GCS  protein (antigen, 25 g/ml) or ConA (5 g/ml) for 72 h and IFN-, IL-4 and nitrite levels in cell supernatants determined by ELISA. Mean values ± SE are shown.
DNA vaccine Stimulus Treatment
pVAXGCS Plasmid alone Infected control
IFN- production
(ng/ml)
Unstimulated 0.34 ± 0.31 0.21 ± 0.11 0.06 ± 0.06
Antigen 1.18 ± 0.47 2.07 ± 0.74 2.35 ± 0.25
ConA  67.06 ± 8.66*** 66.45 ± 7.56*** 67.75 ± 10.67***
IL-4 production (ng/ml) Unstimulated 0.04 ± 0.02 0 .04 ± 0.02 0.06 ± 0.04
Antigen 0.16 ± 0.09 0.03 ± 0.01 0.10 ± 0.04
ConA 3.48 ±  1.00** 1.18 ± 0.91* 1.92 ± 0.76*
Nitrite (M) Unstimulated 3.67 ± 0.40 4.86 ± 0.83 3.71 ± 0.17
Antigen 4.88 ± 0.39 6.15 ± 1.98 3.70 ± 0.44
ConA 26.21 ± 1.29*** 25.96 ± 2.12*** 21.96 ± 2.21***
Recombinant protein vaccine Stimulus Treatment
LdGCS LdGCS-NIV Infected control
IFN- production
(ng/ml)
Unstimulated 1.18 ± 0.44 1.35 ± 0.26 0.90 ± 0.33
Antigen 1.68 ± 0.29 2.79 ± 0.80 2.15 ± 0.76
ConA 9.71 ± 1.50** 13.45 ± 2.39*** 13.26 ± 1.14***
IL-4 production (ng/ml) Unstimulated 0.72 ± 0.60 0.83 ± 0.34 0.22 ± 0.18
Antigen 0.31 ± 0.27 0.89 ± 0.30 0.30 ± 0.19
ConA 1.97 ± 0.35 2.06 ± 0.17 0.15 ± 0.08
Nitrite (M) Unstimulated 15.3 ± 3.0 12.8 ± 1.3 7.2 ± 0.7
Antigen 9.9 ±  3.4 9.7 ± 1.7 6.8 ± 0.8
ConA 21.6 ± 4.9** 21.6 ± 2.4* 17.2 ± 0.7**
* P < 0.05 compared to unstimulated control values.
** P < 0.01 compared to unstimulated control values.
*** P < 0.001 compared to unstimulated control values.
Table 2
The effect of vaccination with different vaccines on the immune responses of L. mexicana infected mice. Mice were vaccinated intramuscularly on days −28 and −14 with
50  g pVAX (plasmid alone), 50 g pVAXGCS, 50 g LdGCS protein or 50 g LdGCS protein incorporated into NIV (LdGCS-NIV) and infected on day 0, along with
infection controls, with 1 × 107 promastigotes (DNA vaccine) or 2 × 106 amastigotes (protein vaccine) L. mexicana. Splenocytes isolated from infected animals at the end of
the  experiment were incubated with medium alone (unstimulated), GCS protein (antigen, 25 g/ml) or ConA (5 g/ml) for 72 h and IFN- IL-4 and nitrite levels in cell
supernatants were determined by ELISA. Mean values ± SE are shown.
DNA vaccine Stimulus Treatment
pVAXGCS Plasmid alone Infected control
IFN- production
(ng/ml)
Unstimulated 0.16 ± 0.12 0 ± 0 0.04 ± 0.04
Antigen 3.06 ± 1.49 2.68 ± 0.61 1.48 ± 0.83
ConA 41.36 ± 3.75*** 42.44 ± 3.8*** 33.22 ± 3.41***
IL-4 production (ng/ml) Unstimulated 0 ± 0 0 ± 0 0 ± 0
Antigen 0.02 ± 0.02 0.01 ± 0.01 0 ± 0
ConA 0.28 ± 0.06 0.14 ± 0.02 1.17 ± 0.05
Nitrite  (M) Unstimulated 3.67 ± 0.40 4.86 ± 0.83 3.71 ± 0.17
Antigen 4.88 ± 0.39 6.15 ± 1.98 3.70 ± 0.44
ConA 26.21 ± 1.29*** 25.96 ± 2.12*** 21.96 ± 2.21***
Recombinant protein vaccine Stimulus Treatment
LdGCS LdGCS-NIV Infected control
IFN- production
(ng/ml)
Unstimulated 0.19 ± 0.08 0.29 ± 0.05 2.59 ± 1.30
Antigen 0.57 ± 0.3 0.63 ± 0.09 1.43 ± 0.96
ConA 2.46 ± 2.1 15.21 ± 0.47*** 5.64 ± 3.75
IL-4  production (ng/ml) Unstimulated 2.38 ± 0.92 2.19 ± 0.23 2.44 ± 1.55
Antigen 2.72 ± 1.38 2.93 ± 0.63 2.48 ± 1.42
ConA 3.58 ± 1.41 4.02 ± 0.89 2.52 ± 1.59
Nitrite  (M) Unstimulated 12.79 ± 3.97 8.32 ± 1.22 16.88 ± 2.66
Antigen 24.83 ± 6.67 18.07 ± 3.47 29.01 ± 5.78
ConA 35.90 ± 6.96 26.37 ± 7.52* 38.66 ± 5.78
* P < 0.05 compared to unstimulated control value.
*** P < 0.001 compared to unstimulated control values.
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ice compared to control values (P < 0.01), with titres being higher
or IgG1 (Fig. 3). Splenocytes from mice immunised with LdGCS or
dGCS-NIV and infected with L. major and stimulated with speciﬁc
ntigen produced similar amounts of IFN-, IL-4 and nitrite as cor-
esponding unstimulated control cells (Table 1). ConA stimulation
f the same cells signiﬁcantly enhanced IFN- (P < 0.01) and nitrite
P < 0.05) levels compared to unstimulated control values but did
ot enhance IL-4 production (Table 1).
Only vaccination with LdGCS-NIV protected mice against
nfection with L. mexicana (P < 0.05) and in this case lesions were
igniﬁcantly lower than control values at three of the six time
oints assessed (Fig. 2). Speciﬁc IgG1 and IgG2a antibody titres
ere enhanced in L. mexicana infected mice immunised with
ither LdGCS or LdGCS-NIV compared to infected control val-
es (P < 0.05), with IgG1 titres being higher than IgG2a titres
Fig. 3). IFN-, IL-4 and nitrite concentrations in cells super-
atants of antigen-stimulated cells and unstimulated controls were
imilar for splenocytes from vaccinated infected mice and infec-
ion controls (Table 2). ConA stimulation of splenocytes from
ice immunised with LdGCS-NIV and infected with L. mexi-
ana produced signiﬁcantly higher amount of IFN- (P < 0.001) and
itrite (P < 0.05) but not IL-4 compared to unstimulated control
ells (Table 2). In contrast similar levels of IL-4, IFN- or nitrite
roduction by splenocytes from mice immunised with LdGCS
nd infected with L. mexicana and unstimulated control cells
Table 2).
. Discussion
In this study the ability of a L. donovani GCS DNA or LdGCS
ecombinant protein vaccine to cross-protect against L. major or L.
exicana was determined. LdGCS was the most effective at pro-
ecting against both species but only if LdGCS was incorporated
nto NIV for L. mexicana. NIV would have acted as an adjuvant and
oosted immune responses perhaps by acting as an antigen depot
t the site of injection or by enhancing antigen uptake and subse-
uent presentation by phagocytic cells. Adjuvants are well known
or their ability to enhance the efﬁcacy of Leishmania vaccines [11].
ifferences in the native GCS expressed by the three Leishma-
ia spp. may  explain the inability (L. mexicana) or relative low
rotective capability (L. major)  of the L. donovani pVAXGCS vac-
ine construct compared to LdGCS treatment. At the genetic level
here is considerable homology between the GCS gene sequence
or the three species (86.7%). However there may  be qualitative
pecies-speciﬁc differences in the secondary or tertiary structure
f GCS expressed or quantitative species-speciﬁc differences in
ntigenic exposure, based on differential protein expression during
nfection or antigen availability for priming immune cells. Studies
ave shown that Leishmania spp. have differences in gene expres-
ion in infected individuals [12]. For example, comparison of gene
xpression in L. infantum and L. major showed that only 10.5% of
enes expressed in the amastigote stage were common and regu-
ation of gene expression in Leishmania can occur at translational
nd post-transcriptional levels, e.g. differences in mRNA stability
13]. Differences in antigen availability for priming immune cells
ay  reﬂect the different tropisms of the parasites within the host
r different relationships between the parasite and host immune
esponses. The results of this study indicate that LdGCS is not nor-
ally antigenic in either L. major or L. mexicana infection as infected
ontrols had very low speciﬁc IgG1 and IgG2a antibody titres to
dGCS over the course of infection.It is possible to characterise murine speciﬁc immune responses
s having a Th1 phenotype (enhanced speciﬁc IgG2a titres,
nhanced IFN- production in lymphocyte proliferative assays
fter antigenic stimulation) or a Th2 phenotype (enhanced speciﬁc 30 (2012) 1357– 1363
IgG1 titres, enhanced IL-4 production in lymphocyte prolifera-
tive assays after antigenic stimulation) based on cytokine and
IgG subtype production [14]. In this study protection in L. major
and L. mexicana was  associated with an enhanced Th1 and Th2
response based on antibody data, with the Th2 response being
predominant, but characterising immune responses on the basis
of cytokine production was  difﬁcult. Protection was  not associ-
ated with IL-4 production in either L. mexicana or L. major nor did
cells from protected animals produce signiﬁcantly higher amounts
of IL-4 after stimulation with the mitogen ConA. The inability of
the protein vaccine to enhance IL-4 production may be signiﬁ-
cant. L. major studies have shown that IL-4 has a role in disease
exacerbation, which is mediated by Th2 cells rather than by induc-
tion of alternatively activated macrophages [15]. IL-4 also has an
exacerbatory role in L. mexicana infection as IL-4 receptor alpha
deﬁcient mice fail to develop lesions. IL-13 was not responsible
for mediating susceptibility in L. mexicana since IL-13 deﬁcient
mice were as susceptible to infection as wild-type mice [16].
CD4+ T cells were found to be responsible for long term con-
trol of lesion growth but a non-T cells population was  found to
control initial lesion development since female mice with IL-4
receptor alpha CD4+ deﬁcient T cells had smaller lesions than their
wild-type counterparts [17]. In this study protection in L. mex-
icana was associated with a Th1 responses as ConA stimulated
cells from LdGCS-NIV vaccinated mice infected with L. mexi-
cana produced signiﬁcantly higher amounts of IFN- compared
to unstimulated controls and the values were three higher than
similar treated cells from infected control animals. Studies using
other leishmanial antigens have correlated cross-protection with
the ability to produce IFN- in L. major [2,11] and L. mexicana [18].
All species of Leishmania reside in macrophages in the mammalian
host therefore parasite clearance can only occur if the infected
macrophage is stimulated to kill the intracellular pathogen. IFN-
is a potent stimulator of macrophage microbial killing mechanisms
and nitric oxide is an important antileishmanial mediator [19]. In
this study nitrite production was used as an indirect measure of
nitric oxide production in lymphocyte proliferation assays and pro-
tection in LdGCS-NIV vaccinated mice infected with L. mexicana
was also associated with the ability to produce signiﬁcantly more
nitrite than unstimulated controls after ConA stimulation. The
inability to correlate protection with the type of immune responses
associated with protection in L. major or L. mexicana may  be related
to the inability of immunisation to produce sterile cure in the ani-
mals. In addition the time when immune responses are determined
can also inﬂuence results. In this study cytokine/nitrite production
was only determined by antigen stimulated splenocytes at the end
of an experiment and it is well known that immune responses show
temporal changes during a normal course of infection for L. major
[20] and L. mexicana [21].
In summary the results of this study indicate that a GCS protein
vaccine would more be suitable than a DNA based vaccine for pro-
tection against L. major and L. mexicana. The level of protection is
too low for clinical use but GCS could be considered as a potential
candidate for a multicomponent vaccine, an approach now recog-
nised as a more likely option for vaccination against Leishmania
[4].  It is possible that a different immunisation schedule or using
a ‘prime-boost’ approach [22], where the DNA vaccine is used to
prime host immune responses and then the recombinant protein is
used to boost the immune response induced, may  increase the efﬁ-
cacy of the protection awarded by a vaccine using L. donovani GCS.
In our studies we  have only assessed the protective capabilities of
LdGCS against three Leishmania spp. but it would be interesting
to assess its activity against L. infantum as there is 87.2% homol-
ogy in its GCS gene sequence and that of L. donovani, L. major,  L.
mexicana. It may  not protect against L. brasiliensis as inclusion of
this species reduces the overall homology to 68.9%.
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